FR13C0032I2 - Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif - Google Patents

Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif

Info

Publication number
FR13C0032I2
FR13C0032I2 FR13C0032C FR13C0032C FR13C0032I2 FR 13C0032 I2 FR13C0032 I2 FR 13C0032I2 FR 13C0032 C FR13C0032 C FR 13C0032C FR 13C0032 C FR13C0032 C FR 13C0032C FR 13C0032 I2 FR13C0032 I2 FR 13C0032I2
Authority
FR
France
Prior art keywords
remedy
acetic acid
active ingredient
overactive bladder
anilide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0032C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0032(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR13C0032I1 publication Critical patent/FR13C0032I1/fr
Application granted granted Critical
Publication of FR13C0032I2 publication Critical patent/FR13C0032I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR13C0032C 2002-11-07 2013-06-19 Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif Active FR13C0032I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
PCT/JP2003/014065 WO2004041276A1 (fr) 2002-11-07 2003-11-04 Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif

Publications (2)

Publication Number Publication Date
FR13C0032I1 FR13C0032I1 (fr) 2013-08-09
FR13C0032I2 true FR13C0032I2 (fr) 2014-03-07

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0032C Active FR13C0032I2 (fr) 2002-11-07 2013-06-19 Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif

Country Status (28)

Country Link
US (5) US7750029B2 (fr)
EP (1) EP1559427B1 (fr)
JP (1) JP3815496B2 (fr)
KR (1) KR100967070B1 (fr)
CN (1) CN100406011C (fr)
AT (1) ATE500827T1 (fr)
AU (1) AU2003284700B2 (fr)
BE (1) BE2013C040I2 (fr)
BR (1) BR0316080A (fr)
CA (1) CA2503570C (fr)
CY (2) CY1111399T1 (fr)
DE (1) DE60336334D1 (fr)
DK (1) DK1559427T3 (fr)
ES (1) ES2360353T3 (fr)
FR (1) FR13C0032I2 (fr)
HU (1) HUS1300027I1 (fr)
IL (1) IL168121A (fr)
LU (1) LU92218I2 (fr)
MX (1) MXPA05004925A (fr)
NL (1) NL300599I2 (fr)
NO (2) NO334948B1 (fr)
NZ (1) NZ539577A (fr)
PL (1) PL211687B1 (fr)
PT (1) PT1559427E (fr)
RU (1) RU2321401C2 (fr)
SI (1) SI1559427T1 (fr)
WO (1) WO2004041276A1 (fr)
ZA (1) ZA200503510B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
ES2393525T3 (es) * 2007-11-02 2012-12-26 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de la vejiga hiperactiva
WO2009081837A1 (fr) 2007-12-21 2009-07-02 Astellas Pharma Inc. Composition pharmaceutique utilisée pour atténuer les symptômes du tractus urinaire inférieur
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2363397A4 (fr) * 2008-11-07 2012-07-11 Dainippon Sumitomo Pharma Co Nouvel agent thérapeutique utile pour un symptôme du tractus urinaire inférieur
US8586760B2 (en) * 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
TR201802207T4 (tr) * 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
JP5849946B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
WO2012156998A2 (fr) * 2011-05-18 2012-11-22 Dr. Reddy's Laboratories Limited Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron
US20150031734A1 (en) 2012-03-30 2015-01-29 Astellas Pharma Inc. Pharmaceutical composition containing mirabegron
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
WO2014132270A2 (fr) * 2013-02-27 2014-09-04 Msn Laboratories Limited Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
WO2015013454A1 (fr) * 2013-07-23 2015-01-29 Allergan, Inc. Méthodes et compositions comprenant de la desmopressine combinée à un agoniste du récepteur adrénergique bêta -3
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (fr) * 2014-04-08 2015-10-15 Suven Life Sciences Limited Procédé amélioré de préparation de 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2-phényléthyl] amino]-éthyl)phényl]acétamide
WO2015162536A1 (fr) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Nouveau procédé de préparation de mirabégron et de son intermédiaire
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
US10286033B2 (en) 2014-11-20 2019-05-14 Serenity Pharmaceuticals, Llc Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) * 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
EP3489224A1 (fr) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Promédicaments mirabegron
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
US11123320B2 (en) 2017-05-31 2021-09-21 Sbi Pharmaceuticals, Co., Ltd. Prophylactic or therapeutic agent for hyperaciive bladder
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
WO2019013583A2 (fr) 2017-07-14 2019-01-17 주식회사 대웅제약 Préparation pharmaceutique et son procédé de préparation
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (fr) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Procédé de préparation de mirabegron énacarbile
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (fr) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du mirabegron

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
HUT69285A (en) 1993-04-26 1995-09-28 Fujisawa Pharmaceutical Co Ethanolamine derivatives, pharmaceutical compns. contg. them and process to prepare the sald compds.
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
KR100483635B1 (ko) 1995-10-26 2005-12-21 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 β3작동약으로서유용한페닐에탄올아민화합물,그의제법및그의제조에서의중간체
US6204285B1 (en) 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
CA2263659A1 (fr) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Remede therapeutique ou preventif contre l'incontinence ou l'elimination urinaire frequente
CA2302496C (fr) * 1997-08-28 2009-12-08 Afferon Corporation Therapie contre l'incontinence urinaire
DK1028111T3 (da) * 1997-10-17 2004-09-20 Yamanouchi Pharma Co Ltd Amidderivater eller salte heraf
DE69818516T2 (de) 1997-12-18 2004-07-08 Kissei Pharmaceutical Co., Ltd., Matsumoto Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
NZ507486A (en) * 1998-04-14 2003-03-28 Kissei Pharmaceutical 2-methylpropionic acid derivatives and pharmaceutical uses thereof
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
CA2362586A1 (fr) * 1999-02-12 2000-08-17 Genset S.A. Marqueurs bialleles derives de regions genomiques porteuses de genes intervenant dans le metabolisme de l'acide arachidonique
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) * 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2646729A1 (fr) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methodes et compositions destinees au traitement de l'incontinence urinaire

Also Published As

Publication number Publication date
KR20050072809A (ko) 2005-07-12
HUS1300027I1 (hu) 2016-08-29
US20110230530A1 (en) 2011-09-22
SI1559427T1 (sl) 2011-06-30
RU2321401C2 (ru) 2008-04-10
ES2360353T3 (es) 2011-06-03
JPWO2004041276A1 (ja) 2006-03-02
USRE44872E1 (en) 2014-04-29
PL376771A1 (pl) 2006-01-09
NO20052691D0 (no) 2005-06-06
WO2004041276A1 (fr) 2004-05-21
DE60336334D1 (de) 2011-04-21
LU92218I9 (fr) 2019-01-17
CN1711085A (zh) 2005-12-21
CN100406011C (zh) 2008-07-30
NO2015001I2 (no) 2015-01-26
AU2003284700B2 (en) 2009-05-28
LU92218I2 (fr) 2014-01-07
KR100967070B1 (ko) 2010-07-01
JP3815496B2 (ja) 2006-08-30
US20060115540A1 (en) 2006-06-01
DK1559427T3 (da) 2011-04-26
US8835474B2 (en) 2014-09-16
EP1559427A4 (fr) 2007-05-30
BE2013C040I2 (fr) 2023-03-07
ATE500827T1 (de) 2011-03-15
IL168121A (en) 2011-12-29
AU2003284700A1 (en) 2004-06-07
NL300599I2 (fr) 2017-01-03
US20090093529A1 (en) 2009-04-09
CY2013023I2 (el) 2015-10-07
EP1559427B1 (fr) 2011-03-09
MXPA05004925A (es) 2005-08-18
PL211687B1 (pl) 2012-06-29
RU2005117367A (ru) 2006-01-20
NO334948B1 (no) 2014-08-04
CA2503570C (fr) 2011-04-19
CA2503570A1 (fr) 2004-05-21
ZA200503510B (en) 2006-12-27
BR0316080A (pt) 2005-09-27
CY2013023I1 (el) 2015-10-07
FR13C0032I1 (fr) 2013-08-09
NO2015001I1 (no) 2015-01-19
US7750029B2 (en) 2010-07-06
NZ539577A (en) 2007-06-29
PT1559427E (pt) 2011-05-27
EP1559427A1 (fr) 2005-08-03
CY1111399T1 (el) 2015-08-05
NO20052691L (no) 2005-07-15

Similar Documents

Publication Publication Date Title
FR13C0032I2 (fr) Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
LTPA2016043I1 (lt) 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
WO2005097763A3 (fr) 1,3,4-oxadiazol-2-ones en tant que modulateurs des ppar delta et leur utilisation
DZ3246A1 (fr) Dérivé heterocyclo-alkylsulfonyle pyrazole en tant qu'agents anti-inflammatoires/analgesiques
ATE317257T1 (de) Verwendung von estern von l-carnitinsäure oder von alkanoyl l-carnitinsäure als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe
IS8232A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
MA29036B1 (fr) Diamides d'acide n-heterocyclylphtalique utilises comme insecticide
WO2011037833A3 (fr) Nouveaux dérivés à substitution n-benzylamide d'acide 2-(acylamido)acétique et d'acides 2-(acylamido)propioniques : agents neurologiques puissants
ATE462414T1 (de) Irbesartan enthaltende feste zubereitung
WO2007134038A3 (fr) Nouvelles formes de sel de (2s)-(4e)-méthyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
WO2009145816A3 (fr) Nouveaux dérivés substitués par n-benzylamide d'acide 2-(acylamido)acétiques et acides 2-(acylamido)propioniques : agents neurologiques puissants
CO6270204A2 (es) Soluciones farmaceuticas orales que contienen telbivudina
FR2883472B1 (fr) Utilisation d'un acide chlorogenique en tant qu'un actif amincissant
IL169496A0 (en) Imino acid derivatives for use as inhibitors of matrix metalloproteinases
IS6284A (is) Meðhöndlun á mígreni með því að gefa alfa-lípósýru eða afleiður hennar
BR0214780A (pt) Sal de ácido cìtrico de um composto terapêutico e composições farmacêuticas deste
MA29560B1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
WO2004039377A8 (fr) Utilisation de derives d'acide sulfonique de piperazine en tant qu'antagonistes ccr1 dans le traitement d'une fibrose, de la maladie d'alzheimer et d'autres troubles
NO20032035D0 (no) Terapeutiske midler for heratokonjunktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens
FR2807041B1 (fr) Procede semi-continu de preparation d'amides d'acides carboxyliques bis-silyles
FR2870455B1 (fr) Composition cosmetique comprenant des vesicules d'acide pantetheine sulfonique
FR2841242B1 (fr) Procede de preparation d'un acide carboxylique insature